Option Care Health (OPCH) Beat Expectations, Is The Stock Fully Priced?

Why Option Care Health stock is in focus after its latest update

Option Care Health (OPCH) is drawing fresh attention after reporting second quarter 2026 results, with revenue, EBITDA, and EPS ahead of expectations, while keeping guidance unchanged and continuing investments in digital tools and infusion clinic expansion.

See our latest analysis for Option Care Health.

Against this backdrop, Option Care Health's recent earnings and buyback activity appear to be supporting improving sentiment. The 90 day share price return of 15.99% contrasts with a year to date share price decline of 26.21% and a 1 year total shareholder return decline of 15.64%.

If this kind of move has you looking beyond a single healthcare stock, it could be a good moment to scan the wider opportunity set through the 43 healthcare AI stocks

After a 90 day rebound but a weaker year to date and 1 year record, the question for Option Care Health now is whether the recent strength has already captured the good news or if valuation still leaves room ahead.

Most Popular Narrative: 16.8% Undervalued

Compared with the recent close at $23.79, the most followed narrative pegs Option Care Health's fair value higher, using a detailed long term cash flow view built on specialty infusion demand and capital deployment.

Investments in technology (AI, analytics, digital infrastructure) and clinical resource efficiency projects are supporting increased operating leverage and process automation, which is improving net margins and cash flow generation.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that fair value gap for Option Care Health? The narrative focuses on compounding earnings, steadier margins and a future profit multiple that assumes investors keep rewarding that profile.

The fair value estimate of $28.58 is built using a 7.26% discount rate and a multi year projection for revenue, earnings and margins that extends out to 2029, with analysts expecting Option Care Health to grow earnings while also reducing its share count over time.

Result: Fair Value of $28.58 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Option Care Health narrative still faces pressure from therapy mix shifts toward lower margin drugs and potential reimbursement changes that could unsettle earnings expectations.

Find out about the key risks to this Option Care Health narrative.

Another View on Option Care Health's Valuation

The earlier narrative leans on long term cash flow forecasts and a fair value of $28.58. A different lens comes from our DCF model, which points to a value of $18.25 per share. On that view, Option Care Health at $23.79 screens as overvalued rather than 16.8% undervalued. Which set of assumptions feels more realistic to you in light of recent earnings volatility and debt levels?

For a closer look at how those cash flows are treated and what would need to change to close this gap, check our SWS DCF model output for Option Care Health. Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Option Care Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mix of optimism and concern around Option Care Health, it makes sense to look at the underlying data yourself and act while the information is fresh. To see both sides clearly, start by reviewing the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Option Care Health?

If Option Care Health has sharpened your focus, now is a good time to widen your watchlist with a few targeted stock ideas using the Simply Wall Street Screener.

• Start building potential income by reviewing companies that stand out as reliable payers through the 8 dividend fortresses.
• Look for potential mispriced opportunities by scanning financially strong companies that appear cheap on key metrics using the 52 high quality undervalued stocks.
• Prioritise resilience by checking companies that score well on financial strength and risk using the 83 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com